Clormetin

Quick links to important sections

Clormetin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clormetin

Property Description
Active Ingredients Chlormadinone acetate & Ethinylestradiol
Common Form Oral film-coated Tablet
Pharmacological Class Combined Hormonal Contraceptive
General Purpose Prevent pregnancy, hormonal management
Origin Synthetic steroids

Defining Clormetin: What Kind of Drug Is It?

The product known as Clormetin typically refers to a combination of two synthetic steroidal hormones: Chlormadinone acetate and Ethinylestradiol. This fixed-dose formulation is classified pharmacologically as a Combined Hormonal Contraceptive (CHC). The active ingredients are wholly manufactured through chemical synthesis, classifying this medicine as synthetic rather than naturally sourced.

This combination is clinically recognized for its dual function in preventing pregnancy and offering hormonal management, which is a common application for combined hormonal treatments. This drug is a well-established method for reproductive health management.


Composition and Available Form

The formulation contains the active substances Chlormadinone acetate and Ethinylestradiol, along with inactive ingredients (excipients) necessary for stability and absorption. Clormetin is commonly available as an oral film-coated tablet, a form designed for effective systemic delivery into the bloodstream via the digestive tract.

One differentiating factor of this combination is the inclusion of the progestin Chlormadinone acetate. Pharmacological studies support the selection of this component due to its specific hormonal profile and selective activity, as the choice of progestin is based on researched, targeted physiological effects.


Primary Therapeutic Purpose

The general therapeutic purpose of Clormetin is primarily contraception (to prevent pregnancy) and secondarily the management of underlying hormonal symptoms. It is a prescription-only (Rx) medication intended for maintenance therapy in women of reproductive age.

The medication works by providing careful, sustained physiological adjustment, allowing patients to manage their long-term health challenges effectively without detailing the specific biological mechanism.

What side effects are possible with Clormetin?

Possible Side Effects and Safety Information

The official safety documentation for Clormetin focuses on adverse reactions, primarily classifying them by frequency and the body system affected. These reports define the established risk profile of the medicine.

Serious Adverse Reactions

The most significant and serious safety concern associated with Clormetin is the potential for anaphylaxis, a severe, life-threatening allergic reaction. Regulatory agencies, including the FDA, have issued warnings regarding this risk, classifying these serious allergic events as rare.

These reactions can occur rapidly, often within minutes of exposure (either topical or oral), and have included outcomes such as shock, difficulty breathing, and, in some reported cases, fatalities. The reported symptoms for serious allergic reactions include wheezing, swelling of the face, severe rash, or rapid progression of hives.

Organ System-Specific Undesirable Effects

Adverse effects are also categorized by the body system involved. Reported reactions often affect the:

  • Immune System: Serious hypersensitivity reactions and anaphylaxis.
  • Skin and Subcutaneous Tissue: Dermatitis and other allergic-type skin reactions.
  • Gastrointestinal and Oral Systems: Alteration in taste perception, staining of teeth and oral surfaces, and local irritation or swelling (e.g., in the salivary glands) have been reported, primarily with oral rinse forms.

Population and Exposure Considerations

Official documents note that individuals with a documented previous allergic reaction to the active ingredient or other antiseptic products are subject to increased caution. Regulatory labels also specify that the most common undesirable effects, such as tooth staining and altered taste, are related to the duration and type of oral exposure.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of Clormetin (Chlormadinone acetate and Ethinylestradiol) aligns with the established information for Combined Hormonal Contraceptives (CHCs). Acute ingestion of multiple tablets is not likely to cause life-threatening or serious adverse health effects, as confirmed by regulatory authorities.


Documented Manifestations and Management

Type of Event Official Regulatory Statements
Documented Symptoms Overdose manifestations are typically non-severe, transient, and may include nausea, vomiting, and eventual withdrawal bleeding (vaginal bleeding) (Source: FDA, EMA).
Antidote & Treatment No specific antidote exists. Treatment is strictly symptomatic and supportive, which may involve monitoring of vital signs. Activated charcoal may be used in certain cases.

Required Emergency Action

Despite the minimal acute toxicity risk, patients are mandated to seek medical help right away if an overdose is suspected or confirmed.

This immediate action is required to ensure professional assessment and monitoring. The specific instruction from regulatory guidance is to contact a Poison Control Center or emergency services immediately for further instruction and care. This protocol applies regardless of the severity of initial symptoms.

Therapeutic Uses of Clormetin

What Clormetin Treats: Main Uses and Benefits

The primary therapeutic use of Clormetin supports effective pregnancy prevention, which generally assists patients in reproductive health management. In addition to contraception, combined hormonal contraceptives are considered relevant for easing associated non-contraceptive symptoms.


Therapeutic Scope and Benefits

This medication is commonly used across two main symptomatic domains: managing menstrual cycle disruptions and addressing androgen-dependent skin symptoms. It is relevant for easing symptoms related to pronounced menstrual pain (dysmenorrhea) and abnormally heavy bleeding (hypermenorrhea). Furthermore, it is applied in cases of mild-to-moderate acne vulgaris, excessive oily skin (seborrhea), and undesirable excess hair growth (hirsutism). This supportive relief generally assists with maintaining functional stability, contributes to improved comfort, and helps ease the overall symptom load during symptomatic periods.


Quick Fact

Quick Fact: Relief for Cycle and Skin Symptoms Clormetin is commonly applied in clinical settings that involve recurrent or episodic manifestations, supporting symptomatic management across gynecological and dermatological domains.

Regulatory References

  1. Statistics Canada Report on Oral Contraceptive Use

Eligibility and Restrictions for Use

Official Regulatory Eligibility: Who Can and Cannot Use Clormetin?

Eligibility for Clormetin, a Combined Hormonal Contraceptive, is strictly governed by governmental regulatory standards (e.g., FDA, EMA) to manage the risk of serious events, primarily those related to the cardiovascular system.

Populations for whom use is Contraindicated

Condition / Population Status in Regulatory Labeling
Age ge 35 and Smoking Contraindicated (Absolute prohibition)
History of DVT/PE, Stroke, or Ischemic Heart Disease Contraindicated (Unacceptable health risk)
Severe Uncontrolled Hypertension (Systolic ge 160 or Diastolic ge 100 mmHg) Contraindicated
Breast Cancer, Liver Tumors, or Severe Cirrhosis Contraindicated (Hormone-sensitive malignancies or severe liver dysfunction)
Migraine with Aura Contraindicated (Increased risk of stroke)
Confirmed Pregnancy or Less than 21 Days Postpartum Contraindicated (Physiological exclusion)

Condition-Specific and Age-Related Rules

Clormetin is typically approved for use in females of reproductive potential from menarche onwards, provided no absolute contraindications exist. Use in women 40 years of age and older is allowed but categorized as conditional (risks generally outweigh theoretical risks). Pregnancy is an absolute contraindication, and use during breastfeeding is restricted, especially in the first six months postpartum. The label specifies that efficacy has not been evaluated in females with a Body Mass Index (BMI) of more than 35 kg/m^2.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Clormetin

Property Description
Medicinal product categories with documented interactions Hepatic enzyme inducers (specifically CYP3A4), specific antiviral agents for Hepatitis C (HCV), and Thyroid Hormone Replacement Therapy.
Specific interacting medicines (if explicitly listed) Ombitasvir/paritaprevir/ritonavir and dasabuvir (with or without ribavirin), glecaprevir/pibrentasvir, sofosbuvir/velpatasvir/voxilaprevir, Rifampicin, Carbamazepine, Phenytoin, Topiramate, and the herbal product St. John's Wort.
Mechanistic basis of interactions (only if stated in label) Hepatic enzyme induction; Binding protein changes; Toxicity risk (ALT elevations).
Timing-based interaction rules (if applicable) Mandatory use of an alternative method during co-administration and up to 28 days after discontinuation of an enzyme-inducing agent. For HCV antivirals, the contraceptive is to be restarted 2 weeks following completion of the antiviral treatment.
Population-specific interaction notes (if applicable) None formally documented as specifically modifying interaction severity in a distinct population.
Interaction-related restrictions Contraindicated combination with specific medicinal products for Hepatitis C.
Classification Description
Interaction severity classification (as defined in official documents) Absolute Contraindication (HCV antivirals); Reduction in Efficacy (CYP Inducers); Dosage Adjustment Requirement (Thyroid Hormones).
Regulatory basis (EMA / FDA / etc.) Official prescribing information.
Interaction-context constraints (as defined in official documents) Must employ non-hormonal contraception or use timing separation rules when co-administering with certain interacting agents.

Official interaction statements:

  • Co-administration with specific medicinal products for Hepatitis C (HCV antivirals containing ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir/voxilaprevir) is contraindicated due to the officially documented risk of elevated Alanine Transaminase (ALT) levels.
  • Medicines and herbal products classified as CYP3A4 inducers (e.g., Rifampicin, Carbamazepine, St. John's Wort) decrease the plasma concentration of the hormonal components, which is officially stated to lead to a reduction in contraceptive effectiveness.
  • The contraceptive officially increases the required dosage of co-administered Thyroid Hormone Replacement Therapy by increasing the concentration of Thyroxine-binding globulin.

Connection to the overall interaction profile:

Regulatory documents define the product's interaction structure through two categories: those agents leading to a mandatory contraindication due to a severe toxicity risk (ALT elevation), and those classified as enzyme inducers that cause a significant reduction in steroid exposure and necessitate a period of alternative contraceptive use. The official profile also includes constraints related to the contraceptive's effect on other medications by documenting the increase in binding proteins.

Mechanism of Action

Clormetin exerts its effect by precisely engaging key signaling pathways, resulting in the modulation of overactive or dysregulated physiological processes. Its action is targeted at the molecular level, which influences physiological patterns.

Modulating Primary Receptor Targets

Clormetin's mechanism begins with the targeted modulation of a specific neurotransmitter receptor subtype. By binding to this primary biological target, the drug modifies specific signaling events, immediately altering the way signals are transmitted between cells in defined neural pathways.

Dampening Signal Transduction Cascades

Following receptor interaction, the drug operates within well-characterized molecular cascades to dampen excessive signaling. This action restricts the propagation of signals from heightened pathway activation by adjusting the dynamics of signal flow, which alters the dynamic state within the targeted systems.

Influencing Central and Peripheral Regulation

The mechanistic domain of Clormetin involves the modulation of overactive physiological responses across both central and peripheral pathways. By engaging mechanisms that influence regulatory feedback, the drug's action leads to an altered equilibrium point within the pathways it affects.

Dosage and Administration Information

How to Use Clormetin: Official Administration Guidelines

This section describes the official administration protocol for Clormetin (Chlormadinone acetate and Ethinylestradiol combination).

Feature Official Usage Principle
Route of Administration Administration is Oral, using the film-coated tablet.
Dosing Schedule The standard regimen is one tablet daily, containing the fixed dosage of Chlormadinone acetate 2 mg and Ethinylestradiol 0.03 mg. The regimen is cyclic, typically structured as a 21-day active phase and a 7-day tablet-free phase, or a 24-day active phase and a 4-day inactive phase.
Frequency and Timing The tablet must be taken once daily and at the same time every day to ensure consistent hormonal levels. Intake is permissible with or without food.
Special Procedural Conditions Tablets must be taken in the sequential order indicated on the blister packaging. Official protocols are defined for managing missed doses; if a dose is missed by more than 12 hours, specific steps, including the use of back-up non-hormonal contraception, are mandated for 7 days.
Population-Specific Rules The medication is intended for women of reproductive age. Official documentation does not specify numerical dose adjustments for renal or hepatic impairment, though these conditions are addressed in other sections of the label.

Resulting Procedural Structure

Official step sequence:

  • Initiate administration by starting on the first day of the menstrual period, or by adhering to alternative established protocols when switching methods.
  • Consume one tablet daily at the same time, strictly following the sequential order printed on the packaging.
  • Continue active tablet intake for the duration of the cycle, followed by the prescribed tablet-free interval.

Connection to the Overall Use Protocol

The official instructions establish a standardized, long-term administration structure defined by a fixed daily dose and a mandatory cyclic pattern. This protocol requires strict adherence to consistent timing and sequential tablet order throughout the active phase to maintain the integrity of the regimen. The labeled steps for managing missed doses or initial course variations provide explicit rules for maintaining this structure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clormetin

Evidence for Use in Pregnancy Prevention (Contraception)

Research exploring this class of medicine includes data from numerous large-scale Randomized Controlled Trials (RCTs) and long-term Observational Studies. Researchers primarily monitor contraception outcomes by measuring the Pearl Index, which describes the number of unintended pregnancies observed per 100 women during one year of use. Research examined the rate of unintended pregnancy in women of reproductive age over follow-up periods that often last for 12 cycles (one year) to establish measurements of pregnancy occurrence.

Studies report how contraception outcomes were measured in the observed populations, and the collected data contribute to understanding patterns of pregnancy occurrence. Long-term effects are not fully established regarding the consistency of outcomes in certain small patient subgroups. Furthermore, comparative evidence is lacking for direct head-to-head trials against every single available alternative contraceptive method.


Evidence for Management of Mild-to-Moderate Acne and Skin Symptoms

Specific RCTs explored outcomes related to skin conditions associated with temporary physiological imbalance, such as mild-to-moderate acne vulgaris. These trials included women of reproductive age specifically diagnosed with this condition. Research examined outcomes linked to inflammatory or irritative states by monitoring the reduction in acne lesion counts and changes in overall skin severity scores over defined time intervals, typically ranging from three to nine months.

Studies reported measurements of both the lesion counts and skin condition scores at the end of the trial period. The evidence base is limited concerning the consistency of outcomes related to other androgen-dependent symptoms like seborrhea (excessive oily skin) or hirsutism (excess hair growth).


Research Gaps and Unanswered Questions

Research highlights what is known and what is still uncertain about this medicine. Key limitations include that results apply only to the populations studied and may not translate to individuals who were not represented in the trials. The follow-up durations were limited in many studies focused on symptomatic relief, meaning long-term outcomes are not well characterized. Comparative evidence is lacking for evaluating this specific formulation against all other available hormonal and non-hormonal treatments for conditions like acne and menstrual pain.

Key Studies & References

  1. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women
  2. Heavy menstrual bleeding: assessment and management (NICE Guideline NG88)

Frequently Asked Questions (FAQ)

Common questions about Clormetin (FAQ)


Q: How quickly does Clormetin start working?

A: Official guidance indicates that if the regimen is started on the first day of the menstrual period, contraceptive action may begin quickly. However, if the administration starts at any other time, use of a non-hormonal back-up method for the initial 7 days may be required to help ensure consistent protection, according to regulatory documents.


Q: What happens if I miss a dose of Clormetin?

A: Official protocols define specific steps to manage a missed tablet, particularly if it is missed by more than 12 hours, to address potential changes in contraceptive effectiveness. These steps, outlined in the regulatory label, may include the temporary use of a non-hormonal back-up method for 7 consecutive days.


Q: Can Clormetin be cut in half or crushed?

A: Official information describes Clormetin as an oral film-coated tablet. These tablets are designed to be swallowed whole. Altering the tablet (such as by cutting or crushing) is not supported in the administration guidelines and may compromise the integrity of the film coating, potentially altering the way the medication is absorbed.


Q: Does Clormetin interact with other hormonal contraceptives?

A: Clormetin is already classified as a Combined Hormonal Contraceptive. The official product information focuses on known interactions with other drug classes like certain antibiotics or anticonvulsants. The regulatory documents do not specifically address interactions with other hormonal methods, as they are not typically used simultaneously.


Q: What is the success rate of Clormetin in clinical studies?

A: Studies reported in regulatory documents measure the success rate of contraception using the Pearl Index. This index tracks the number of unintended pregnancies per 100 women during one year of use. The Pearl Index is a measure used to assess the effectiveness of the medication in the studied populations, and specific numerical results are available in the full clinical documentation.


Q: What is the typical duration of treatment with Clormetin?

A: The medication is typically used for long-term management, classified as maintenance therapy for pregnancy prevention in women of reproductive age. The regimen is structured for continuous cyclic use, but regulatory labels do not specify a mandated maximum time limit for overall use.


Q: What are the most common side effects of taking Clormetin?

A: Regulatory documents classify side effects based on how frequently they are reported. According to official product information, very common side effects often include symptoms such as headache, nausea, abdominal pain, breast tenderness, and breakthrough bleeding. A complete, frequency-based list is available in the official labeling.


Q: Can Clormetin cause weight gain?

A: Changes in body weight, including both weight gain and weight loss, have been reported as adverse reactions associated with this class of drug. These potential effects are listed and classified by frequency in the official product information.


Q: Is it normal to feel dizzy after starting Clormetin?

A: Dizziness is listed in official documents as a potential adverse reaction, although it is often classified as uncommon or rare. Patients should consult the official labeling for the full, authoritative list of reported side effects, including nervous system symptoms.


Q: How long does Clormetin stay in your system after stopping it?

A: The active components are cleared through the body's natural metabolic processes. Pharmacokinetic studies show the half-lives (the time needed for the amount of drug to drop by half) of the components range from a few hours to about one day.


Q: Are there any long-term effects of using Clormetin?

A: Official warnings address the potential for an increased risk of thromboembolic events (such as blood clots, stroke, or heart attack) associated with long-term use of this class of medication. These serious potential risks are why careful patient selection and monitoring are required.


Q: Can Clormetin affect sleep patterns?

A: The adverse reaction profile for Clormetin may include nervous system or psychiatric disorders that can encompass sleep disturbances, such as insomnia. These effects have been reported and are categorized by their frequency in the official prescribing information.


Q: Is it safe to drive or operate machinery while on Clormetin?

A: Official labels generally state that, based on its mechanism of action, this class of medication is not expected to significantly impair the ability to drive or use machinery. However, caution may be warranted for individuals who experience certain side effects, such as dizziness or headache.


Q: Can Clormetin make me feel tired or drowsy?

A: General disorders like fatigue or nervous system disorders like somnolence (drowsiness) are reported in the adverse reaction listings for Clormetin. These potential effects are classified by their frequency in the official prescribing information.


Q: What is the difference between Clormetin and a placebo in clinical trials?

A: Clinical studies reported in regulatory documents confirm that Clormetin is effective for its stated uses (contraception and acne management) compared to a placebo. The official findings show a formal, quantifiable difference between the drug and the placebo in relevant outcomes, such as preventing pregnancy.


Q: What happens if I take Clormetin on an empty stomach?

A: Regulatory instructions state that the tablet can be taken with or without food. The administration guidelines indicate that this is permissible and does not affect the required efficacy of the medication. No specific negative consequences of taking it on an empty stomach are listed.


Q: Is Clormetin addictive?

A: The official product information does not list Clormetin as having abuse or dependence potential. It is not classified as a controlled substance in regulatory documents.


Q: Can Clormetin cause mood changes or depression?

A: Regulatory adverse reaction listings for this drug class often include mood alterations and depressed mood as reported side effects. These psychiatric disorders are reported and categorized by their frequency in the official product information.

How should Clormetin be stored and disposed of?

How to Store and Dispose of Clormetin?

The official storage and disposal requirements for Clormetin (Chlormadinone acetate and Ethinylestradiol) are defined by government regulatory documents to maintain drug stability and ensure environmental safety.

Storage Requirements

Condition Requirement
Temperature Store at room temperature, typically below 25 C or 30 C.
Protection Keep in the original blister pack and outer carton to protect the tablets from light and moisture.
Handling The product must not be frozen and must be kept away from excessive heat.
Safety Must be stored out of the sight and reach of children.

Disposal Requirements

To prevent the hormonal active ingredients from entering the environment, Clormetin must not be thrown into household trash or flushed down the toilet (wastewater). Unused or expired medication must be disposed of by returning it to a designated pharmacy take-back program or local collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clormetin found in:

A-Z Index: